L'intérêt à découvert pour InMed Pharmaceuticals donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de InMed Pharmaceuticals. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

InMed Pharmaceuticals (NASDAQ:INM) Stock, Rapport sur les intérêts à découvert

InMed Pharmaceuticals

InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.

InMed Pharmaceuticals Inc. - Common Shares

InMed Pharmaceuticals Inc

INmune Bio Inc

InMode Ltd

Rokeby Resources Ltd

iShares Intermediate Muni Income Active ETF

WIIM

BOOT

Boot Barn Holdings shares are trading higher after the company reported better-than-expected Q1 financial results, issued Q2 guidance above estimates, and raised its FY26 guidance.

ENVX

Enovix shares are trading lower after the company released its Q2 financial results.

News

Guidance

ICFI

ICF International Raises FY2025 GAAP EPS Guidance from $5.24-$5.82 to $5.82 vs $5.27 Est

ICF International Raises FY2025 Adj EPS Guidance from $6.71-$7.45 to $7.45 vs $6.89 Est; FY2025  Revenue expected to be more than $1.818B vs $1.912B Est

Eastman Chemical shares are trading lower after the company reported worse-than-expected Q2 financial results and issued Q3 adjusted EPS guidance below estimates.

Riot Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $(0.10) by 658.82 percent. This is a 278.12 percent increase over losses of $(0.32) per share from the same period last year. The company reported quarterly sales of $152.988 million which beat the analyst consensus estimate of $147.650 million by 3.62 percent. This is a 118.50 percent increase over sales of $70.018 million the same period last year.

Earnings

Earnings Beats

RIOT

Riot Platforms Q2 EPS $0.57 Beats $(0.10) Estimate, Sales $152.988M Beat $147.650M Estimate

Roku (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) raises FY2025 sales outlook from $4.550 billion to $4.650 billion vs $4.555 billion estimate.

ROKU

CORRECTION: Roku Raises FY2025 Sales Guidance from $4.550B to $4.650B vs $4.555B Est

Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) reported third-quarter financial results after the market close on Thursday. Here&#8217;s a look at the key details from the <a href="https://www.benzinga.com/pressreleases/25/07/b46775533/apple-reports-third-quarter-results">tech giant&#8217;s report</a>.
Q3 Earnings: Apple reported fiscal third-quarter revenue of $94 billion, beating analyst&nbsp;<a href="https://www.benzinga.com/quote/AAPL/earnings" target="_blank" rel="noreferrer noopener">estimates</a>&nbsp;of $89.04 billion. The iPhone maker reported third-quarter earnings of $1.57 per share, beating analyst estimates of $1.42 per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Total revenue was up 10% year-over-year, and earnings per share climbed 12% year-over-year. Americas sales totaled $41.2 billion in the quarter, Europe sales came in at $24.01 billion, Greater China sales were approximately $15.37 billion, Japan sales totaled $5.78 billion and the rest of Asia Pacific sales were $7.67 billion.
Apple noted that its active installed base of devices once again reached new all-time highs across all products and geographic segments. The company attributed the growth to high levels of customer satisfaction and loyalty.
Products revenue came in at $66.61 billion, up from $61.56 billion year-over-year. Services revenue totaled $27.42 billion, up from $24.21 billion year-over-year. Here's a breakdown of product sales by category:
<ul class="wp-block-list">
<li>iPhone: $44.58 billion, versus $39.3 billion last year</li>
<li>Mac: $8.05 billion, versus $7.01 billion last year</li>
<li>iPad: $6.58 billion, versus $7.16 billion last year</li>
<li>Wearables, Home and Accessories: $7.4 billion, versus $8.1 billion last year</li>
</ul>
&#8220;Today Apple is proud to report a June quarter revenue record with double-digit growth in iPhone, Mac and Services and growth around the world, in every geographic segment,&#8221; said&nbsp;Tim Cook, CEO of Apple.
&#8220;At WWDC25, we were excited to introduce a beautiful new software design that extends across all of our platforms, and we announced even more great Apple Intelligence features.&#8221;
Apple ended the quarter with $36.27 billion in cash and cash equivalents. The company&#8217;s board declared a quarterly cash dividend of&nbsp;26 cents&nbsp;per share, payable on Aug. 14 to shareholders of record as of Aug. 11.
Apple has an earnings call scheduled for 5 p.m. ET. A link to the third-quarter call can be found below. The company tends to provide commentary on the call on how it generally expects its different product lines to perform over the coming months.
AAPL Price Action: <a href="http://benzinga.com/quote/aapl" target="_blank" rel="noreferrer noopener">Apple shares</a> were up 3% in after-hours, trading at $213.79 at the time of publication Thursday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/07/46766944/stock-market-outlook-sp500-august-seasonality-magnificent-seven">Stock Market Outlook: July&#8217;s Highs Mask A Dangerous August Twist</a></li>
</ul>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46680504/apple-faces-18-month-deadline-to-deliver-on-ai-says-analyst">Apple Faces 18-Month Deadline To Deliver On AI, Says Analyst</a></li>
</ul>
Photo: hanohiki/Shutterstock.com
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Apple Earnings Call Q3 2025 &#x7C; $AAPL &#x7C; &#x1f534; WATCH LIVE" width="500" height="281" src="https://www.youtube.com/embed/DgePMQwv-m8?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>

Movers

Tech

AAPL

Apple Q3 Earnings: Revenue, EPS Smash Estimates As iPhone Sales Jump, Active Installed Base Reaches New Highs

Management

Wells Fargo Appoints Charlie Scharf As Chairman

On July 24, 2025, Future FinTech Group Inc. (the "Company") entered into a securities purchase agreement (the "Equity SPA") with certain institutional and individual investors (each, a "Purchaser"), pursuant to which the Company agreed to issue and sell, and the Purchasers agreed to purchase, up to an aggregate of 15,000,000 shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), at a purchase price of $2.00 per share. No significant shareholder or officer of the Company participated in the First Transaction. The initial closing is capped at no more than 19.9% of the Company's outstanding Common Stock as of the closing date (the "19.9% Limit") and with the issuance of the remaining shares of Common Stock pursuant to the Equity SPA subject to shareholder approval as explained below.
 &nbsp;

General

FTFT

Future FinTech Group Entered Securities Purchase Agreement With Institutional And Individual Investors Up To 15M Shares At $2/Share

Mercer Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MERC#NASDAQ">MERC</a>) reported quarterly losses of $(1.29) per share which missed the analyst consensus estimate of $(0.87) by 48.28 percent. This is a 27.72 percent decrease over losses of $(1.01) per share from the same period last year. The company reported quarterly sales of $453.52 million which missed the analyst consensus estimate of $514.00 million by 11.77 percent. This is a 9.18 percent decrease over sales of $499.38 million the same period last year.

Earnings Misses

MERC

Mercer Intl Q2 EPS $(1.29) Misses $(0.87) Estimate, Sales $453.52M Miss $514.00M Estimate

WisdomTree (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WT#NYSE">WT</a>) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.17 by 2.86 percent. This is a 12.5 percent increase over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $112.621 million which beat the analyst consensus estimate of $111.370 million by 1.12 percent. This is a 5.22 percent increase over sales of $107.034 million the same period last year.

WisdomTree Q2 Adj. EPS $0.18 Beats $0.17 Estimate, Sales $112.621M Beat $111.370M Estimate

Astrotech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTC#NASDAQ">ASTC</a>), a provider of next generation security screening and detection technologies based on Mass Spectrometry ("Mass Spec"), today announced the first sale and deployment of its TRACER 1000&#x2122; Narcotics Trace Detector ("TRACER 1000 NTD&#x2122;") in Vietnam, by way of its subsidiary 1st Detect. This milestone marks a significant step in expanding the 1st&nbsp;Detect footprint across Southeast Asia and reinforces its commitment to enhancing narcotics trace detection inspection capabilities in global emerging markets.
"This first NTD system in Vietnam demonstrates Astrotech's growing presence in Asia and the increasing trust commercial and critical infrastructure operators are placing in our advanced technology," said Tom Pickens, CEO of Astrotech Corp. "We are honored to support Vietnam's security modernization efforts with next generation Mass Spec based trace detection and comprehensive library capabilities to deliver the accuracy, breadth and speed needed to counter the global narcotics trade."
"The global narcotics and explosives trace detection market is estimated at more than $7 billion1 and growing rapidly, driven by a strong demand for innovation as law enforcement and public safety agencies combat an ever growing range of drugs and explosives," said Pickens. "1st Detect offers a highly differentiated solution that not only provides the precision and reliability of Mass Spec analysis to clearly and accurately identify a substance, but also a virtually unlimited library capability to support the detection of new concerns and threats as they are identified in this fast-evolving marketplace."
TRACER 1000 NTD&#x2122;, designed for confirmatory trace narcotics detection, enables security authorities to detect threats, contraband, and illicit materials with near-zero false alarm rate. 1st Detect's goal is to ensure that detection is future proof and gives authorities confidence in its results due to the highly precise nature of the Mass Spec technology.

Asset Sales

ASTC

Astrotech Corporation Announces The First Sale And Deployment Of Its Tracer 1000 Narcotics Trace Detector In Vietnam, By Way Of Its Subsidiary 1st Detect

Cryptocurrency trading platform company Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) reported second-quarter financial results after <a href="https://www.benzinga.com/earnings">market close Thursday.</a>
Here are the highlights.
 What Happened: Coinbase reported second-quarter revenue of $1.5 billion, down 26% quarter-over-quarter. The revenue missed a Street consensus estimate of $1.69 billion, according to data<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0731"> from Benzinga Pro.</a>
Transaction revenue in the quarter was $764 million, down 39% quarter-over-quarter.
Subscription and services revenue was $656 million, down 6% quarter-over-quarter.
Trading volume was $237 billion in the quarter, down 40% quarter-over-quarter.
Transaction revenue was down year-over-year for both the consumer and institutional segments. The company said crypto spot volume was down 31% globally and 32% in the U.S. year-over-year.
The company ended the second quarter with $9.3 billion in USDC (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>) and $1.8 billion in crypto assets, which includes weekly Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) purchases.
Adjusted earnings per share of 12 cents missed the Street consensus estimate of $1.35.
Coinbase said its derivatives trading volume hit all-time highs in the quarter.
The company highlighted its growing USDC adoption, Base Chain going live in more places and scaling, the launch of Base APP in open beta with over 700,000 on the waitlist, and various cryptocurrency legislation pieces, including the GENIUS Act, signed into law.
"These bills provide a clear regulatory foundation for stablecoins and digital assets, potentially unlocking new opportunities for Coinbase and reinforcing U.S. leadership in digital finance," the company said.
Trading volume by cryptocurrency was:
<ul class="wp-block-list">
<li>Bitcoin: 30%</li>
<li>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>): 15%</li>
<li>Other: 55%</li>
</ul>
This compares to the first quarter, where Bitcoin was 27%, Ethereum was 11% and XRP Coin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) was 11%
Transaction revenue by cryptocurrency was:
<ul class="wp-block-list">
<li>Bitcoin: 34%</li>
<li>Ethereum: 12%</li>
<li>XRP:13%</li>
<li>Other: 41%</li>
</ul>
This compares to the first quarter when Bitcoin was 26%, Ethereum was 10%, Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) was 10% and XRP was 18%.
Read Also: <a href="https://www.benzinga.com/trading-ideas/previews/25/07/46742773/coinbase-q2-preview-can-white-house-momentum-bitcoin-all-time-highs-help">Coinbase Q2 Preview: Can White House Momentum, Bitcoin All-Time Highs Help?</a>
What's Next: Coinbase said it expects July transaction revenue to be $360 million.
The company is guiding for third-quarter subscription and services revenue to be in the range of $665 million to $745 million, surpassing the levels of the second quarter. The growth is attributed to higher cryptocurrency prices and stablecoin revenue.
Coinbase is guiding for higher expenses for the third quarter with higher headcount.
"The opportunities for growth have expanded substantially with increased regulatory clarity. We are taking this opportunity to grow headcount in exciting areas we expect to become meaningful in the future, including international expansion," the company said.
COIN Price Action: Coinbase stock is down 5.8% to $356.04 in after-hours trading Thursday versus a 52-week trading range of $142.58 to $444.64.
 Read Next: 
<ul class="wp-block-list">
<li>&nbsp;<a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46721901/jpmorgan-partners-with-coinbase-to-expand-crypto-access-for-80m-customers" target="_blank" rel="noreferrer noopener">JPMorgan Partners With Coinbase To Expand Crypto Access For 80M Customers</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$SOL

$USDC

$XRP

COIN

Coinbase Q2 Earnings Highlights: Sales, EPS Miss, 40% Slide In Trading Volume

<a href="https://www.bloomberg.com/news/articles/2025-07-31/trump-asks-bank-ceos-to-pitch-on-fannie-freddie-stock-offerings" title="https://www.bloomberg.com/news/articles/2025-07-31/trump-asks-bank-ceos-to-pitch-on-fannie-freddie-stock-offerings">https://www.bloomberg.com/news/articles/2025-07-31/trump-asks-bank-ceos-to-pitch-on-fannie-freddie-stock-offerings</a>

FMCC

FNMA

'Trump Asks Bank CEOs to Pitch on Fannie, Freddie Stock Offerings' - Bloomberg News

Board Authorizes Purchase of Up to 3 Million Shares of Common Stock

Buybacks

AREN

The Arena Group Authorizes 3M Share Repurchase Program

- Purchases 4.9% of Great Elm Group's Common Stock; $150 Million Debt Investment in Monomoy Properties REIT to Accelerate Industrial Real Estate Platform Expansion –
- Company to Host Conference Call at 8:30 a.m. ET on August 1, 2025 -
Transaction Highlights:
<ul>
<li>Certain funds affiliated with Kennedy Lewis Investment Management LLC ("KLIM") purchase 4.9% of Great Elm Group, Inc's ("GEG") outstanding common stock at market price, approximately $2.11 per share.</li>
<li>$150 million of term loans in total strategic financing for Monomoy Properties REIT, LLC ("Monomoy REIT") from KLIM to catalyze growth across the Monomoy industrial real estate platform recently consolidated under Great Elm Real Estate Ventures, LLC ("Real Estate Ventures")</li>
<li>KLIM appoints board representatives at both GEG and Monomoy REIT, underscoring its commitment to a long-term partnership &nbsp;</li>
</ul>
PALM BEACH GARDENS, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- &nbsp;Great Elm Group, Inc. ("we," "us," "our," "GEG" or "Great Elm,") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEG#NASDAQ">GEG</a>), a publicly traded alternative asset manager, today announced a transformational strategic partnership with KLIM, an institutional alternative investment firm focused on opportunistic credit strategies including real estate with over $30 billion in assets under management. This partnership delivers up to $150 million in leverageable capital to support continued growth across Great Elm's real estate platform, which includes Monomoy REIT, Monomoy CRE (MCRE), Monomoy Construction Services (MCS), and Monomoy BTS (MBTS) (together "Monomoy"). Monomoy offers a full-service suite of project management, procurement, construction management, asset management, market analysis and feasibility services for its industrial real estate tenants.
Under the terms of the transaction, KLIM is providing an initial $100 million term loan to Monomoy REIT, and the option for an additional $50 million in future capital. Additionally, KLIM is purchasing 4.9% of GEG's common stock at market price, approximately $2.11 a share, and will hold an initial 15% profits interest (which may be increased to 20% under certain circumstances) in the newly formed Great Elm Real Estate Ventures, LLC, which consolidates GEG's real estate subsidiaries: MCRE, MCS, and MBTS.

Kennedy Lewis Invests $150M In Monomoy REIT, Acquires 4.9% Stake In Great Elm Group To Accelerate Industrial Real Estate Growth

RKLB

Rocket Lab Opens Window For Its Next Mission For Multi-launch Customer, Institute For Q-shu Pioneers Of Space, Marking Electron's 69th Mission To Date And 11th Launch This Year

MODG

Topgolf Callaway Brands CEO Artie Starrs To Resign

<ul>
<li>Leqvio can now be used alone, without addition of statin therapy, as adjunct to diet and exercise for LDL-C reduction in patients with hypercholesterolemia (high LDL-C)1 &nbsp;</li>
<li>4 out of 5 atherosclerotic cardiovascular disease (ASCVD) patients do not reach guideline-recommended LDL-C target, reinforcing urgent need for more aggressive LDL-C lowering2-5 &nbsp;</li>
<li>Twice-yearly Leqvio is uniquely positioned to help support patient adherence and long-term LDL-C management, including goal attainment</li>
</ul>
Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio&#xAE; (inclisiran), enabling its use as monotherapy along with diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia1. The FDA proactively requested the label update based on the robust LDL-C lowering data for PCSK9-targeting therapies.
"This first-line label update reinforces Leqvio's proven ability to effectively lower LDL-C, a critical risk factor for heart disease," said Victor Bultó, President, US, Novartis. "With this new indication enabling Leqvio's use as monotherapy along with diet and exercise, we now have the potential to help even more patients achieve their LDL-C lowering goals earlier in their treatment journey."
With its twice-yearly, health care provider-administered dosing, Leqvio is uniquely positioned to help support patient adherence and long-term LDL-C management, including goal attainment. This is a critical unmet need, as up to 80% of ASCVD patients in the US struggle to reach the LDL-C guideline-recommended target of &lt;70 mg/dL2-5. This need is heightened by the latest 2025 ACC/AHA Joint Committee Clinical Practice Guideline for the Management of Patients with Acute Coronary Syndromes, which recommends more aggressive treatment to achieve LDL-C targets6.
The updated label removes the requirement for Leqvio to be used on top of or in combination with statin therapy1. Other updates include revising "primary hyperlipidemia" to the more specific term of "hypercholesterolemia" throughout the label, to more accurately focus on LDL-C reduction1.

Biotech

Novartis Announces That The U.S FDA  Has Approved A Label Update For Leqvio Allowing Its Use As Monotherapy Along With Diet And Exercise To Reduce Low-Density Lipoprotein Cholesterol In Adults With Hypercholesterolemia1.

InMed Demonstrates Encouraging Data For Its Cannabinoid INM-089 In Treating Dry AMD, An Ocular Disease With Rising Patient Numbers As National Population Ages

Press Releases

InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study

InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules

Screenshot 2024-08-27 at 5.44.40 PM

Screenshot 2024-07-18 at 5.31.04 PM

Cannabis

Markets

The Rising Importance Of Minor Cannabinoids In The Growing Edible Market

Screenshot 2024-05-06 at 5.34.20 PM

InMed (NASDAQ: INM) Developing Cannabinoids Analogs To Treat Alzheimer&#39;s – New Studies Showcase INM-901&#39;s Therapeutic Abilities

Comments

InMed Pharmaceuticals

Intérêt court

InMed Pharmaceuticals (NASDAQ:INM) Stock, Rapport sur les intérêts à découvert

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL